AI-discovered molecules are entering clinical trials at 80–90% Phase I success rates — against a historical average of 52%. In January 2026 alone, Eli Lilly, GSK, and Pfizer each signed major AI platform deals. The hype cycle is over. The clinical validation cycle has begun. This letter presents three fundamentally strong positions across the pharma spectrum — not as recommendations, but as the honest investment case for a long-horizon reader who wants to understand what they are buying and why.
Not investment advice. Not a recommendation to buy or sell. Research and long-horizon thinking only. Consult a qualified financial advisor before making any investment decision. All financial data from publicly available sources as of June 2026.
For three years, AI drug discovery was a story about potential. Dozens of companies claimed to be using machine learning to find better drug candidates faster. Most of them were pre-revenue platforms with no human clinical data. The venture market flooded the space with capital. The signal was buried in noise.
In 2026 that changed. The data arrived. Over 173 AI-originated drug programs are now in clinical development — up from just 24 in late 2023. Phase I success rates for AI-discovered molecules are running at 80–90%, against the historical industry average of 52%. The discovery-to-clinic timeline has compressed from a historical average of four to six years to as little as eighteen months. McKinsey estimates generative AI could save the pharmaceutical industry $60 billion annually in R&D costs at full deployment.
The implications for established pharmaceutical companies are profound. A company that reduces its failure rate from 90% to 20% does not just save money — it produces more approved drugs per dollar invested, compounds its pipeline faster, and builds a durable earnings growth rate that the market has not yet fully priced. The question for the long-horizon investor is not whether AI transforms pharma. It is which companies are embedding AI most deeply — and whether the market has noticed yet.
"A company that reduces its drug failure rate from 90% to 20% does not just save money. It produces more approved drugs per dollar invested — and compounds its pipeline faster than the market has priced."
GSK is the most systematically undervalued major pharmaceutical company in the world. The market has not yet priced the structural change underway in its R&D engine — and that gap between reality and perception is where the long-horizon investor finds opportunity.
In January 2026, GSK signed two transformative AI deals in a single week. A multi-year collaboration with genomics company Helix, gaining access to GenoSphere cohorts of genomic and longitudinal data for precision medicine R&D. And a five-year $50 million partnership with AI-native biotech Noetik — giving GSK access to virtual cell models that can predict how cancer patients respond to therapies before a single drug is given. These are not experiments. They are infrastructure investments that will generate compound returns through the 2030s.
The genetics-driven pipeline is the most important story. Wave Life Sciences collaboration targeting frontotemporal dementia and non-small cell lung cancer. Computational biology reducing the 90% historical failure rate in early-stage development. IDRx acquisition bringing a Phase III gastrointestinal stromal tumour asset. Efimosfermin for steatotic liver disease in Phase III trials. GSK is building the discovery engine of the future while trading at a discount to peers who have not yet made these investments.
Pfizer is the most misunderstood major pharmaceutical company in 2026. The market is pricing it as a post-COVID casualty — a company that had a once-in-a-generation revenue windfall from vaccines, spent aggressively to diversify, and is now managing the hangover. That framing is not wrong about the past. It is wrong about the future.
The January 2026 partnership with Boltz — deploying generative AI for small molecule drug discovery — gives Pfizer access to one of the most capable AI discovery platforms available. Chai Discovery's Chai-3 model, licensed by Pfizer, doubles antibody design success rates and enables the targeting of proteins previously considered undruggable. These are not marginal improvements. They are step changes in what is scientifically possible — and Pfizer now has proprietary access to them.
The pipeline is more interesting than the market gives it credit for. Weight-loss candidate MET-097i shows better tolerability than GLP-1 competitors in early data — addressing the side effect profile that limits Ozempic adoption in certain patient populations. Oncology assets acquired through the Seagen acquisition ($43B in 2023) are entering late-stage trials. Pfizer at $145B is pricing in continued decline. The pipeline does not support that thesis.
Sun Pharma is the India position in the pharma portfolio — and it is the most compelling emerging market pharmaceutical story for the long-horizon investor. India's largest pharmaceutical company, Sun operates at the intersection of three powerful tailwinds: the global generics market where India has structural cost advantages, the US specialty drug market where complex generics command premium margins, and the biosimilars transition that is just beginning.
The US market is Sun's most important growth driver. Complex generics — injectables, transdermal patches, ophthalmics — require the kind of manufacturing precision and regulatory relationship-building that takes decades to develop. Sun has those relationships. Their US speciality business in dermatology, ophthalmology, and oncology is growing at double digits. The pipeline of complex generics awaiting FDA approval is substantial.
The India domestic business provides a stable, growing foundation. As India's population ages and its middle class expands, healthcare expenditure grows proportionally. Sun's distribution network across tier-2 and tier-3 cities is an asset that no new entrant can replicate quickly. Sun Pharma is the picks-and-shovels play on India's healthcare expansion — a business that benefits whether India's growth comes from pharma innovation, generics demand, or the biosimilars transition.
These three positions are not selected arbitrarily. They represent three distinct points on the pharma spectrum — each addressing a different risk-return profile, each connected to the same underlying structural trend.
GSK is the genetics and AI infrastructure bet — a Western major rebuilding its discovery engine with the most advanced tools available, trading at a discount because the market has not yet seen the clinical output. Patient capital buys the transformation before it is priced.
Pfizer is the recovery and optionality bet — a company at a sentiment low with a genuine pipeline and a generative AI moat in small molecule discovery. The dividend provides income while the pipeline matures. The Seagen oncology assets provide upside if the ADC modality continues to prove itself in late-stage trials.
Sun Pharma is the emerging market structural growth bet — India's healthcare expansion measured in decades, not quarters. The complex generics moat is real and expensive to replicate. The biosimilars pipeline is the next chapter. The currency of this position is patience and India conviction.
Together they provide exposure to Western AI drug discovery infrastructure, Western pipeline recovery, and emerging market healthcare growth — three different return drivers, each fundamentally strong, each connected to the Trillion-Dollar Pharma Race trajectory we have outlined.
The pharmaceutical industry is in the middle of its most significant transformation since the discovery of antibiotics. AI is not changing the destination — drugs that cure disease. It is compressing the journey. The companies that embed AI most deeply, and the investors who back them before the market fully prices the transformation, will compound through the decade.
Written from first principles. Not consensus. Not noise. Long-horizon thinking on capital, technology, and the forces shaping the next decade of wealth creation. Published when something is worth saying — not on a schedule.